HB and Alpha Tau Medical partner to bring the world’s first Alpha Radiation Brachytherapy to Japan

HekaBio K.K. partnered with Alpha Tau Medical LTD, an Israeli company, to establish Alpha Tau Medical K.K in Japan on January 31, 2018. The purpose of Alpha Tau Medical K.K. is to supply and distribute to the Japanese market a highly potent and conformal alpha radiation-based cancer treatment, the Alpha DaRT.

Alpha Tau Medical LTD (Tel Aviv, Israel) developed the world’s first brachytherapy using alpha radiation for the treatment of solid cancers, including pancreatic, prostate, head & neck and other cancers. The treatment, Alpha DaRT (Diffusing Alpha-Emitters Radiation Therapy), is under clinical research in the EU, Asia and the United States. Clinical trials currently conducted in Europe and Israel confirm the efficacy and safety of the treatment.

Alpha DaRT therapy is effective for all solid carcinomas tested, including hypoxic tumors. Radioactive Alpha DaRT seeds are directly inserted into the tumor, releasing alpha particles and causing immediate destruction of cancer cell DNA while sparing surrounding healthy tissue.

Development and Clinical trial planning is are progressing in Japan with major cancer centers.


About Alpha Tau Medical LTD

Alpha Tau Medical is an Israeli medical device company that focuses on research, development and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid tumor cancers. The Alpha DaRT technology was developed by Prof. Itzhak Kelson and Prof. Yona Keisari in 2003 at Tel Aviv University.

Alpha Tau Medical’s mission is “to enable a cancer treatment that destroys tumors while sparing healthy tissue to save the lives of millions of patients around the world.” (Alpha Tau Medical, Mission Statement)


For more information, please visit http://www.alphataumedical.com/ (English Only)


About the Alpha DaRT treatment

The Alpha DaRT treatment has several important features:

• Highly potent and conformal

• Proven efficacy for all solid tumors tested

• Effective regardless of tumor oxygen level

• Short half-life – quick clinical outcome

• No known negative systemic effects

• Stimulates anti-tumor immune response

• Single-session treatment

• Enables combination with other therapies or reapplication

• Disposable applicators - does not require capital equipment or special shielding


About HekaBio K.K.

Office: Yashima Bldg. 3F, 2-7-14 Toranomon, Minato-ku, Tokyo 105-0001

Tel: +81 (3) 6205-7585 Fax: +81 (3) 6205-7586

Chief Executive Officer: Robert E. Claar

HekaBio focuses on cancer, autoimmune/ inflammatory and central nervous system disease. The management team has extensive experience and networks, both overseas and in Japan.

With a deep understanding and respect for Japanese medical needs and business practices, HekaBio continues to grow by developing its innovation pipeline with validated programs from overseas partners. HekaBio strives to eliminate the innovation gap between Japan and rest of the world with the swift launch of therapies meeting unmet medical needs in Japan.

With integrity and tenacity, HekaBio collaborates with healthcare and business partners to creatively address the unmet medical needs of patients who are fighting rare and intractable diseases.

最新記事

すべて表示

コスモ・ピーアール、ヘカバイオに出資両社が戦略的パートナーシップを締結

~バイオサイエンスの新たなイノベーションについて認知度とアクセシビリティの向上を図る~ 2020年9月23日 ヘカバイオ株式会社(本社:東京都中央区、代表取締役兼CEO:クレア・ロバート、以下:ヘカバイオ)と株式会社コスモ・ピーアール(本社:東京都港区、代表取締役社長:佐藤玖美、以下:コスモ)は、コスモがヘカバイオに出資し、両社が戦略的パートナーシップを締結したことを発表します。本パートナーシップ

オフィス移転のお知らせ Office Relocation

2020年8月24日より下記へ移転いたします。 〒103-0021 東京都中央区日本橋本石町3丁目3番16号 日本橋室町ビル8階 電話番号・FAX番号 変更無し 最寄り駅: 地下鉄各線 三越前駅 A8出口 徒歩3分 Effective August 24, 2020, HekaBio will relocate to new premises as follows. Nihonbashi Muro

治験実施施設追加のお知らせ

アルファ粒子線源を用いた新たな放射線治療の治験実施施設に、東北大学病院が追加されました。 詳しくはこちらへ

ヘカバイオ株式会社

〒103-0021

東京都中央区日本橋本石町3-3-16

日本橋室町ビル8階

LI-Logo.png

© 2020 HekaBio K. K.​